Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS).
Eleuterio FerranniniSimona BaldiTiziana ScozzaroVasilis TsimihodimosFisseha TesfayeWayne ShawNorman RosenthalGemma A FigtreeBruce C NealKenneth W MahaffeyVlado PerkovicMichael K HansenPublished in: Diabetes care (2022)
A constitutive metabolic setup consisting of higher lipolysis may be beneficial in delaying or preventing hospitalized HF; a further stimulation of lipolysis by canagliflozin may reinforce this influence.